Does Vraylar Cause Atrial Fibrillation?
No, Vraylar (cariprazine) does not appear to cause atrial fibrillation based on available evidence. The FDA drug label does not list atrial fibrillation as a known adverse effect, and clinical trial data do not demonstrate an association between Vraylar and AFib 1.
Evidence from FDA Drug Label
The official Vraylar prescribing information comprehensively lists adverse reactions from clinical trials across multiple indications (schizophrenia, bipolar disorder, major depressive disorder) and does not mention atrial fibrillation among reported adverse events 1. The cardiovascular adverse effects documented include:
- Orthostatic hypotension (though infrequent and not more common than placebo) 1
- Syncope (not observed in trials) 1
- Monitoring recommendations focus on orthostatic vital signs in vulnerable patients, but no specific cardiac rhythm monitoring is required 1
Context: Antipsychotics and Atrial Fibrillation Risk
While some antipsychotic medications have been associated with AFib, the evidence is limited and primarily involves other agents 2:
- Second-generation antipsychotics as a class showed increased AFib risk in observational studies, with clozapine (adjusted OR 2.81), olanzapine (1.81), quetiapine (1.55), and risperidone (1.25) showing the highest associations 2
- Cariprazine is not mentioned in the 2024 comprehensive review of drug-induced atrial fibrillation published in Pharmacological Research, which extensively catalogued medications known to cause AFib 2
Clinical Implications
For patients on Vraylar, routine cardiac rhythm monitoring specifically for AFib is not indicated based on current evidence 1. However, standard cardiovascular monitoring remains appropriate:
- Monitor orthostatic vital signs in elderly patients, those with dehydration, hypovolemia, or on antihypertensive medications 1
- Assess patients with known cardiovascular disease (myocardial infarction history, ischemic heart disease, heart failure, conduction abnormalities) 1
- Complete fall risk assessments due to potential somnolence and postural hypotension 1
Important Caveats
If a patient on Vraylar develops new-onset AFib, consider alternative explanations 2:
- Underlying cardiac risk factors (age, hypertension, structural heart disease, diabetes) 2
- Concomitant medications that may cause drug-induced AFib 2
- Other medical conditions (hyperthyroidism, pulmonary embolism, alcohol use) 2
The absence of AFib in Vraylar's adverse event profile across extensive clinical trials provides reassurance that this medication does not carry a clinically significant AFib risk 1.